Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

By H. Phillips, S. Kharbanda, Ruihuan Chen, W. Forrest, R. Soriano, Thomas D. Wu, A. Misra, J. Nigro, H. Colman, L. Soroceanu and 4 more. Cancer Cell, 2006

3,123 citations recorded by the source corpus.

Subfields: Cancer Research, Developmental Neuroscience, Genetics

View Paper: https://www.semanticscholar.org/paper/ffac7252cffce925cea46817e5d415eeda45a9da

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Developmental Neuroscience

In Genetics

Citations in the corpus

Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. (2008, background): “Profiling studies have shown that gliomas express many genes known to play a role in neural progenitor cells ( 5 ).”
Glioma Subclassifications and Their Clinical Significance (2017, background): “[39] published their findings of potentially 3 divisions within gliomas based on gene expression microarray: proneural, proliferative, and mesenchymal/angiogenic.”
An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors (2008, background): “In the breast and brain, this signature was detected in tumor subtypes previously suggested to arise from oligopotent stem or progenitor cell”
Molecular subgroups of medulloblastoma: the current consensus (2011, background): “…transcriptional approach to tumor sub-classiﬁcation has also been applied to a number of different non-medullo-blastoma histologies [4, 16, 18, 31, 35, 43], with the underlying assumption that tumors with similar transcriptomes will behave in a biologically similar manner, allowing a…”
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics (2013, background): “Furthermore, patterns of gene expression have been collated to identify molecular subgroups with putative prognostic or predictive significance (5, 6).”
Malignant astrocytic glioma: genetics, biology, and paths to treatment. (2007, background): “…have facilitated the identification of specific genes that predict survival, such as FABP7, DLL, and ASPM (Liang et al. 2005; Horvath et al. 2006; Phillips et al. 2006) and permit one to predict the clinical response to EGFR kinase inhibitors (Haas-Kogan et al. 2005; Mellinghoff et al. 2005).”
Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. (2009, background): “Molecular profiling of GBM tumors has suggested distinct subclasses of the disease (Mischel et al., 2003; Louis, 2006; Phillips et al., 2006).”
Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment (2017, background): “Comparison of pairs of initial gliomas and first disease recurrence did not identify the trend of PNGBM transitioning to aMESphenotype that has often been suspected (Phillips et al., 2006).”
An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1 (2010, methodology): “…and gene expression profiling studies identifying gene signatures associated with EGFR overexpression, clinical features, and survival (Freije et al., 2004; Liang et al., 2005; Mischel et al., 2003; Murat et al., 2008; Nutt et al., 2003; Phillips et al., 2006; Shai et al., 2003; Tso et al., 2006).”
PrognoScan: a new database for meta-analysis of the prognostic value of genes (2009, background): “As of February 2009, the collection included more than 40 datasets of various cancer types spanning a wide range of cancers including bladder, blood, breast, brain, esophagus, head and neck, kidney, lung, and ovarian (Table 1) [10-35], far more comprehensive than both ITTACA, which focuses on bladde”
Pathway-based personalized analysis of cancer (2013, background): “Neural and proneural samples are thought to have better prognosis (20, 21); the pathway-based substrati ﬁ cation reveals, however, that this notion is due to a subset of better survivors (logrank P value < 0.05).”